This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
$1 buys you full access to ALL of TheStreet's Subscription Services! Learn More

Health Winners & Losers: ImClone

Stocks in this article: IMCLLLYBMY

Biotech stocks dropped as the markets plummeted at the start of the week, though some stock success stories broke through.

The Nasdaq and Amex biotechnology indices were down 5.3% and 4.9%, respectively. The Nasdaq global biotechnology index was off by 5.6%.

The only stock in the green on the Amex index was ImClone Systems (IMCL), which tacked on $1.75, or 2.7%, to $6.71 after Eli Lilly (LLY) confirmed that it bid $70 a share or roughly $6.1 billion. Eli Lilly said the offer represents a premium of 51% to ImClone's closing stock price on July 30, the day before Bristol-Myers Squibb's (BMY) acquisition offer for ImClone was made public.

Meanwhile, Bristol-Myers Squibb, which had launched a hostile tender for $62 a share, indicated it would not raise its offer. But it also isn't walking away empty-handed. The company said it owns roughly 14.4 million shares, or 16.6%, of ImClone. Considering that, the transaction is worth about $1 billion in cash for Bristol-Myers.

Eli Lilly shares were down 5.4% to $39.16. Meanwhile, Bristol-Myers shares gave up 4.5% to $19.51.

Turning to study results, the wait for interim data from Dendreon (DNDN) is over. Dendreon shares soared $2.67, or 52%, to $7.87, after the company said prostate cancer vaccine Provenge had a 20% reduction in the risk of death at the interim analysis. The FDA required a 22% reduction in order to grant approval based on these mid-study data, so the trial will continue, with investors waiting for a final readout in 2009.

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,803.16 -11.78 -0.07%
S&P 500 2,068.70 +1.67 0.08%
NASDAQ 4,771.9680 +13.7160 0.29%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs